Advisory Service of the Health and Safety Executive (courtesy of Dr K Campion). Six were associated with previous exposure to thorium dioxide (Thorotrast) and two to vinyl chloride monomer. All diagnoses had been agreed by a panel of pathologists (PP Anthony, RNM MacSween, and PJ Scheuer). Five were referred for consultation and were diagnosed by the same criteria. Of seven cases of MEH, one came from the Angiosarcoma Register, two from personal experience, and four had been referred for consultation. All seven had been previously investigated and diagnosed by published criteria, four by more than one expert liver pathologist.
Archival material, stained by haematoxylin and eosin, Gordon & Sweet's reticulin, periodic acid Schiff reagent and, in some cases, by VWF or UEA-1, was re-examined.
A polyclonal rabbit antibody to VWF (Dakopatts) was used at a 1 in 400 dilution. UEA-1 (Dakopatts) was used at a dilution of 1 in 400 and rabbit anti-UEA-1 (Dakopatts) at a dilution of 1 in 300. Biotinylated swine antirabbit antibody (Dakopatts) was used as a (fig  2A) , or as tongue-like projections within vessels ( fig 2B) . Intracytoplasmic lumina in small groups of tumour cells were also readily shown (Fig 2C) .
VWF stained angiosarcoma moderately, with an overall score of 1-83; only two cases reacted well and one not at all. Staining was :, generally patchy and granular and was best seen in solid areas (fig 3) . Malignant haemangioendotheliomas reacted somewhat better, with a score of 2 0; staining was again patchy.
UEA-1 performed as well as VWF in angiosarcomas with an average score of 1-89, and very well in malignant haemangioendotheliomas with a score of 2-57. Staining was crisp in all histological patterns of these two tumours. In 16 of 26 cases tested, however, bile duct epithelium or blood cells also stained strongly (fig 4) .
Discussion
Malignant vascular tumours of the liver are rare, but they are the commonest sarcomas at this site and they have attracted much interest recently for two main reasons.'8 One concerns aetiology. The main known aetiological agent of "classic" angiosarcoma is thorium dioxide (Thorotrast), a radiological contrast medium, that has been in use since the late 1920s: it is radioactive and emits alpha particles over the lifetime of those exposed to it. The peak incidence may have been passed but new cases continue to appear. The number of people at risk is unknown but it was estimated to be between 50,000 and 100,000 not long ago.'9 Occupational exposure to vinyl chloride monomer is next in importance. The discovery of this hazard in the early 1970s led to the establishment of survey schemes and registers in the United States, Germany, Great Britain and more recently, in Japan. Other agents, like arsenic, copper in vintner's sprays, and rarely, drugs, are of much lesser importance.'8 Angiosarcoma of the liver is therefore one of the most important examples of a malignant tumour induced by medical treatment and by industrial exposure to a known agent.
The second reason for continuing interest is difficulty in diagnosis: only one third of the cases submitted to the Angiosarcoma Panel of the Health and Safety Executive were confirmed. 20 The same applies even more to malignant haemangioendothelioma. This tumour produces such variability in histological appearance that almost no two cases are exactly alike and new features of it continue to be described.2' Recognition is important as amenability to treatment is greater and prognosis is better than is the case for either angiosarcoma or other malignant tumours of the liver.
Immunocytochemistry 4 QB-END/10 avoids most of the difficulties encountered with VWF and UEA-1 and is both specific and sensitive. All histological patterns of angiosarcoma and malignant haemangioendothelioma have been shown to stain clearly and well. For the time being and until more experience has been gained, however, it would be wise to use QB-END/10 in conjunction with VWF and UEA-1, but, in this study at least, QB-END/10 has proved superior to both.
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